Table 1. pDCs but not cDCs exposed to a low dose of IFN-β prior to TLR ligand activation demonstrate DC activation priming.
cDCs | IFN-α | IFN-β | TNF-α | IL-6 | IP-10 | MIP-1β | RANTES | RIG-I | MXA |
PR8 | 28.45 | 13.61 | 7.13 | 8.64 | 37.72 | 9.66 | n/d | 7.14 | 12.88 |
PR8-UV | 0.00 | 0.00 | 0.64 | 0.59 | 2.16 | 0.44 | 0.75 | 0.92 | 1.97 |
poly I∶C | 0.90 | 2.12 | 1.08 | 1.20 | 1.58 | 0.73 | 0.56 | 0.63 | 0.85 |
CL-075 | 0.00 | 0.00 | 3.01 | 4.06 | 0.17 | 0.80 | 3.28 | 1.42 | 1.82 |
LPS | 0.53 | 1.75 | 2.10 | 0.51 | 0.84 | 0.91 | 0.69 | 0.37 | 0.56 |
cDCs and pDCs were pretreated with IFN-β (50 units/ml) 3 hours prior to treatment with live influenza PR8 virus, or UV-inactivated influenza, or LPS, or CpG, or poly (I∶C), or CL-075 Gardiquimod (Gard). The robustness of priming is given as the fold increase of mRNA expression of IFN+TLR ligand over the amount of expression from the IFN alone sample and TLR alone samples [IFN+TLR ligand sample / (IFN alone sample+TLR alone sample)]. Data are representative of at least two independent experiments in which both dose and time courses of activation were done. n/d signifies not determined.